Amphastar Pharmaceuticals(DE:29A)
€25.27-1.86 (-6.86%)
DE:29A
Amphastar Pharmaceuticals stock drug pipeline
€25.27
At close:-1.86 (-6.86%)
Amphastar Pharmaceuticals (29A) Drug Pipeline
2 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| I004, Novolog | Pharmacokinetics, Pharmacodynamics, Insulin Aspart | phase2AndPhase3 | Completed | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers | Apr 24, 2026 | ― |
| I004, Novolog | Pharmacokinetics, Pharmacodynamics | phase2AndPhase3 | Completed | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers | Sep 12, 2022 | ― |
| Epinephrine, Epinephrine Injection Auto-Injector, Albuterol Sulfate | Asthma, Pharmacokinetics, Epinephrine, Albuterol, Anaphylaxis | Phase IV | Completed | Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals | Dec 19, 2019 | ― |
| A006 Dpi, Proventil Mdi | Asthma | Phase II | Completed | Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers | Oct 20, 2014 | ― |
| A006 Dpi, Proventil Mdi | Asthma | Phase II | Completed | Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation | Aug 04, 2014 | ― |
| Epinephrine Hfa-Mdi | Asthma | Phase III | Completed | Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma | Nov 20, 2012 | ― |
| Arm T Epinephrine Inhalation Aerosol Hfa, 125 Mcg, 1 Inhalation, Arm C-Epinephrine Inhalation Aerosol Cfc | Asthma | phase1AndPhase2 | Terminated | Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults | Nov 20, 2012 | ― |
| Saline, Hyaluronidase, Histamine | Allergic Skin Reaction | Phase II | Completed | Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) | Sep 13, 2012 | ― |
| Albuterol Dpi 25 Mcg/Inh, Albuterol Dpi 90 Mcg/Inh, Albuterol Mdi 90 Mcg/Inh | Asthma | Phase II | Completed | Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation | Apr 17, 2012 | ― |
| Primatene Mist, Epinephrine Inhalation | Asthma | Phase III | Completed | Safety Study in Adolescent and Adult Patients With Asthma | Nov 15, 2011 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| I004, Novolog | phase2AndPhase3 | Pharmacokinetics, Pharmacodynamics, Insulin Aspart | Completed | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers | Apr 24, 2026 | ― |
| I004, Novolog | phase2AndPhase3 | Pharmacokinetics, Pharmacodynamics | Completed | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers | Sep 12, 2022 | ― |
| Epinephrine, Epinephrine Injection Auto-Injector, Albuterol Sulfate | Phase IV | Asthma, Pharmacokinetics, Epinephrine, Albuterol, Anaphylaxis | Completed | Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals | Dec 19, 2019 | ― |
| A006 Dpi, Proventil Mdi | Phase II | Asthma | Completed | Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers | Oct 20, 2014 | ― |
| A006 Dpi, Proventil Mdi | Phase II | Asthma | Completed | Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation | Aug 04, 2014 | ― |
| Epinephrine Hfa-Mdi | Phase III | Asthma | Completed | Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma | Nov 20, 2012 | ― |
| Arm T Epinephrine Inhalation Aerosol Hfa, 125 Mcg, 1 Inhalation, Arm C-Epinephrine Inhalation Aerosol Cfc | phase1AndPhase2 | Asthma | Terminated | Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults | Nov 20, 2012 | ― |
| Saline, Hyaluronidase, Histamine | Phase II | Allergic Skin Reaction | Completed | Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) | Sep 13, 2012 | ― |
| Albuterol Dpi 25 Mcg/Inh, Albuterol Dpi 90 Mcg/Inh, Albuterol Mdi 90 Mcg/Inh | Phase II | Asthma | Completed | Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation | Apr 17, 2012 | ― |
| Primatene Mist, Epinephrine Inhalation | Phase III | Asthma | Completed | Safety Study in Adolescent and Adult Patients With Asthma | Nov 15, 2011 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Amphastar Pharmaceuticals Inc (DE:29A) have in its pipeline
Amphastar Pharmaceuticals DE:29A is currently developing the following drugs: I004, Novolog, Epinephrine, Epinephrine Injection Auto-Injector, Albuterol Sulfate, A006 Dpi, Proventil Mdi, Epinephrine Hfa-Mdi, Arm T Epinephrine Inhalation Aerosol Hfa, 125 Mcg, 1 Inhalation, Arm C-Epinephrine Inhalation Aerosol Cfc, Saline, Hyaluronidase, Histamine, Albuterol Dpi 25 Mcg/Inh, Albuterol Dpi 90 Mcg/Inh, Albuterol Mdi 90 Mcg/Inh, Primatene Mist, Epinephrine Inhalation, E004 Hfa-Mdi, Epinephrine Inhalation Aerosol, Arm T1: Primatene Mist Hfa, Arm T2: Primatene Mist Hfa, Arm C: Primatene Mist, Epinephrine Inhalation Aerosol, Epinephrine Inhalation Aerosol, Hfa, A006, Proventil-Hfa, Albuterol Inhalation Powder, Albuterol Inhalation Aerosol, E004, 90 Mcg/Actuation, E004, 125 Mcg, E004, 220 Mcg, Epinephrine Inhalation Aerosol, Cfc Propelled, E004, 160 Mcg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

